The effect of inhaled bromhexine on clinical symptoms and recovery of COVID-19

The effect of inhaled bromhexine on clinical and laboratory symptoms and COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230514058188N1

Enrollment

Registered

2023-06-13

Start date

2023-06-10

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspnea. Abnormalities of breathing

Interventions

Intervention 1: Intervention group: Patients will receive bromhexine hydrochloride solution for inhalation (Mucolin ampoule 4 mg/2 ml, manufactured by Daru Pharmaceutical Company, Iran) 8 mg every 8 h

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with COVID-19 confirmed by PCR Patients with respiratory symptoms including caugh and dyspnea

Exclusion criteria

Exclusion criteria: Need to mechanical ventilation Pregnancy or lactating Peptic ulcer

Design outcomes

Primary

Measure	Time frame
Cough Severity. Timepoint: Before intervention and daily up to 7 day after intervention. Method of measurement: Visual Analogue Score.	—

Secondary

Measure	Time frame
Arterial blood O2 saturation. Timepoint: Before intervention and daily up to 7 days after intervention. Method of measurement: Atrial blood gas measurment.;Arterial blood carbon dioxide level. Timepoint: Before intervention and daily up to 7 days after intervention. Method of measurement: Atrial blood gas measurment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Memarian

Semnan University of Medical Sciences

draria2014@gmail.com+98 23 3142 2120

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026